Aurora kinases are conserved eukaryotic serine-threonine kinases, which serve as key regulators of mammalian mitosis. Several studies revealed a distinct correlation between inaccurate chromosome segregation, leading to chromosomal number instability, cancer progression and poor outcome. The aim of this study was to investigate the correlation of Aurora kinases A (AURKA) and B (AURKB) with overall survival (OS) by quantifying gene expression analysis and evaluation of single-nucleotide polymorphisms (SNPs) in human colorectal cancer samples and assessing the associations with clinicopathological features. We evaluated intratumoral gene expression levels and SNPs of AURKA and -B from 41 patients with metastatic colorectal cancer (mCRC). Patients with a high expression level of AURKB (41.28) lived significantly shorter (n ¼ 11, median OS ¼ 6.4 months, 95% confidence interval (CI): 3.0-14.5 months) compared with patients with a low expression level (p1.28) (n ¼ 30, median OS ¼ 18.4 months, 95% CI: 14.7-27.8 months, P ¼ 0.026, Wald's test). Patients harboring any G-allele in AURKB 885A4G showed a significantly decreased OS (P ¼ 0.05, log-rank test). We did not find any associations with clinicopathological variables and AURKA gene expression levels. Our results suggest a potential role for AURKB inhibition in patients with mCRC; thereby supporting its potential role as a target in mCRC.
Introduction
Many genetic alterations in pathways regulating cell growth, tissue renewal and apoptosis have been found to be the hallmarks of cell transformation and carcinogenesis. 1 Among these alterations, the dysregulation of the mechanisms responsible for cell segregation is frequently observed in malignant cells. 2 Recent evidence suggests a group of serine-threonine kinases, known as Aurora kinases, to have an important role in carcinogenesis as key regulators of mammalian mitosis, crucial for identical and exact segregation of genomic material during cell division. 3 It is proposed that aberrations of chromosome segregation potentially causes aneuploidy and is therefore triggering carcinogenesis. 4 Thus, it is not unexpected that these kinases have been described to be related with chromosomal instability, agressive growth and poor outcome in leukemia and in various malignancies like breast, bladder, ovarian, pancreatic and colon cancer. 1, [5] [6] [7] [8] This group of kinases consists of three highly related kinases, known as AURKA (alias STK6/STK15/AurA), AURKB (alias STK12/STK5/AurB) and AURKC (alias STK13/AurC) in mammals. AURKA and -B are expressed in the majority of normal cell types. However, AURKC is mostly expressed in testis, suggesting a specific function in the regulation of chromosomal segregation of male meiosis. 4, 9 The regulatory facets of AURKA and -B include centrosome duplication, mitotic spindle formation, mitotic checkpoint activation and cytokinesis. 1 Notwithstanding the fact that AURKA and -B vary from each other regarding the localization and time point of activation during mitosis, they regulate the cell-cycle progression in a coordinated manner. 9 AURKA is localized on chromosome 20q13, a region frequently amplified by tumors. 10 During mitosis, AURKA is primarily localized to the centrosomes. 2 Several studies relating to transfection identified AURKA in vivo and in vitro as a veritable oncogene;
1,10 as overexpression of AURKA has been shown to multiply centrosome production.
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Furthermore this increase of centrosome production has been linked with the generation of a chromosomal instability (CIN) phenotype. 12, 13 AURKB is found on chromosome 17p13, an area not typically amplified by tumors. 3 Beside the lack of amplification on gene level, several studies revealed an overexpression of mRNA and protein levels in several malignancies, associated with lymph node invasion, proliferation and metastasis.
14-18 AURKB belongs to the family of chromosomal passenger proteins and is essential for accurate chromosomal segregation and orientation, spindle assembly checkpoint, chromosome condensation, nuclear envelope formation and cytokinesis. 3, 19, 20 There is not much information available regarding polymorphisms in both genes. A single-nucleotide polymorphism in AURKA, AURKA Phe31Ile, has been described as a candidate low-penetrance tumor-susceptibility gene in breast-, prostate-, ovarian-, lung-, esophageal-, nonmelanoma skin-and colon cancer. 21 Furthermore, a recent manuscript described a single-nucleotide polymorphism in AURKB (AURKB 885A4G) to be associated with an increased risk of breast cancer. 22 On the basis of these informations, we hypothesized that coding variants of AURKA and -B and intratumoral gene expression levels may have an impact on clinical outcome in patients with metastatic colorectal cancer.
Materials and methods

Patients
There were 41 consecutive patients with primary colorectal adenocarcinoma who were treated between 1999 and 2003 at the University of Southern California/Norris Comprehensive Cancer Center (USC/NCCC) or the Los Angeles County/University of Southern California Medical Center (LAC/USCMC), who were eligible for this study. Only metastatic or recurrent patients were included. This study was completed at the USC/NCCC and approved by the Institutional review Board of the University of Southern California for Medical Sciences. Patient follow-up information and clinical data were collected retrospectively through chart review; all patients signed an informed consent.
A majoring of the patients (32 of 41 patients, 78%) was initially treated at an outside institution until, because of previous treatment failure; they were referred to USC/NCCC or LAC/USCMC for future treatments. Although the chemotherapy regimens varied in patients, all patients received with 5-fluorouracil-based combination chemotherapy. Most of them received either 5-fluorouracil/irinotecan or 5-fluorouracil/oxaliplatin.
Microdissection
Formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained from 41 patients. Tissue samples used for the evaluation of gene expression levels were obtained from the primary tumor at the time of diagnosis. After a review of representative hematoxylin-and eosin-stained slides of the FFPE blocks by a pathologist, 10 mm-thick sections were obtained from the identified areas with the highest tumorload for laser-captured microdissection (P.A.L.M. Microlaser Technologies AG, Munich, Germany), according to a standard procedure. The dissected tissue was then processed in a reaction tube containing 400 ml of RNA lysis buffer. 23 Isolation of RNA and cDNA synthesis RNA isolation from FFPE samples was accomplished according to a patented procedure of Response Genetics (Los Angeles, CA, USA; patent no. 6248, 535). After RNA isolation, cDNA synthesis was executed as previously described. 24 RT-PCR quantification of mRNA expression The quantification of AURKA and -B expression levels were completed by using an internal housekeeping gene (b-actin) and our gene-set in a fluorescence-based real time detection method (ABI prism 7900 Sequence Detection System, (TaqMan) Perkin-Elmer Applied Biosystem, Foster City, CA, USA). The RT-PCR was performed as previously described, 24 primers and probes are listed in Table 1 . TaqMan measurements are resulting in cycle threshold (Ct) values that are inversely correlated to the amount of cDNA in the sample, that is, a high Ct value implies more PCR cycles to run until the fluorescent signal exceeds the threshold and is therefore detected.
Gene expression values (relative mRNA levels) are expressed as ratios (differences between the Ct values) between the gene of interest and b-actin, used as an internal reference gene to provide a normalization factor for the amount of RNA isolated from a specimen. 23 All samples were run in triplicates.
Isolation of genomic DNA and genotyping Whole blood was available from 38 out of 41 patients. Genomic DNA was isolated using the QiaAmp kit (Qiagen, Valencia, CA, USA). Forward and reverse primers were used
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Statistical analysis Primary endpoint of this study was overall survival (OS).
This was calculated as the difference between the dates of first treatment for metastatic colorectal cancer at USC/NCCC or LAC/USCMC and the date of last follow-up respectively date of death from disease. The association between AURKA and -B gene expression was examined by using the Spearmen correlation coefficient. The associations between AURKA and -B and OS were analyzed using KaplanMeier curves and Cox's proportional hazards model. The associations between genomic polymorphisms and clinicodemographic parameters were assessed using contingency tables and the Fisher's exact test. Correlation of the genotypes with OS was examined individually using Kaplan-Meier curves and the log-rank test. The estimate of relative risk (RR) with 95% confidence intervals (Cis) was based on the log-rank test for the univariate analysis. 25 Linkage disequilibrium between the two AURKB polymorphisms was analyzed using D' and r 2 values and interpreted utilizing the program Haploview version 3.32 (www.broad.mit.edu/mpg/haploview). Haplotype frequencies and haplotype dosage estimates were inferred using EM algorithm (20) . The w 2 test was used to examine whether the allele frequencies observed in three polymorphisms were within the probability limits of Hardy-Weinberg equilibrium. The Cox proportional hazards regression model was used to evaluate the association between gene expression, polymorphisms and OS when adjusting previous treatment.
This study was conducted to test whether AURKA and -B were prognostic factors in patients with metastatic colon cancer. With 41 patients with AURKA and -B gene expression values measured and OS available (37 events), we have 80% power to detect a hazard ratio of 2.52 when comparing OS between two groups of patients using a two-sided 0.05 level log-rank test. To simplify power calculation, we assume that half patients carried unfavorable marker with shorter survival.
The reported P-values were two-sided. All analyses were performed using the SAS statistical package version 9.0 (SAS Institute, Cary, NC, USA) and Epilog Plus Version 1.0 (Epicenter Software, Pasadena, CA, USA).
Results
This study population consists of 41 patients, 21 women (51%) and 20 men (49%). Median age at time of diagnosis was 55 years, with a range from 25 to 76 years. The racial/ethnic distributions of study participants were: 32 Whites, (78%), 5 Asians (12%), 3 Hispanics (7%), and 1 African-American (2%, Table 3 ). The median follow-up in these patients was 3.5 years (range: 2.3-5.9 years). Of the 41 patients, 37 patients had died and the median OS was 15.1 months (95% CI: 13.0-22.7 months). Four patients were still alive at the time of the last follow up.
Gene expression levels of AURKA and -B AURKA and -B expression levels were both quantifiable in 41 patients. The median gene expression levels of AURKA and -B were 1.09 (range:0-9.03), and 0.97 (0.01-5.93), respectively. The expression levels of AURKA and -B were significantly related (Spearman's correlation coefficient ¼ 0.55, Po0.001).
Gene expression levels of AURKA and -B and survival The gene expression level of AURKB was significantly associated with OS based on Cox's proportional hazards model (P ¼ 0.026, Wald's test). Increased expression level Figure 1 ).
There were no significant associations between gene expression levels of AURKA and survival based on Cox's proportional hazards model (P ¼ 0.36, Wald's test, Figure 2 ).
Genetic variants in AURKA and -B and survival
Genotyping for AURKA and -B polymorphisms was successful in 38 of 41 patients. AURKA 1712T4A, AURKB 885A4G and AURKB 893G4A were evaluated with consideration to gene expression levels and OS. None of the polymorphisms tested showed a significant association with gene expression levels. In univariate analysis, patients carrying any G-allele in AURKB 885A4G showed a significant decreased OS, (P ¼ 0.05, log-rank test). Patients homozygous for the A-allele showed a better OS (n ¼ 12, median OS 27.8 months) compared with patients with the A/G genotype (n ¼ 21, median OS 14.7 months) or G/G genotype (n ¼ 5, median OS 16.3 months, Figure 3 ). However, in multivariate analysis, this finding could not be confirmed to be independent from previous treatment (P ¼ 0.84, Cox's proportional hazards model). Allele frequencies were 41.3% for AURKB 885A4G, 24.1% for AURKB 893G4A and 29.3% for AURKA 1712T4A for each variant allele in the white study population. There were no significant associations between clinical outcome and AURKA 1712T4A and AURKB 893G4A (Table 4) .
Haplotype analysis AURKB 885A4G and 893G4A variants showed a strong linkage disquilibrium, with a D' value of 1.0 and a r 2 value of 0.518. Haplotypes were constructed from those two polymorphisms. The three common haplotypes were Not estimated.
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analyzed and accounted for 100% of all haplotypes. Patients carrying the G-G haplotype showed an increased risk of dying compared with patients carrying the A-G allele (RR þ 3.08, Table 5 ).
Discussion
These data suggest the potential clinical significance of AURKA-and -B in patients with metastatic colorectal cancer.
To the best of our knowledge, we were the first to describe a significant association between AURKB activity and OS in colon cancer. This observation showed significant survival benefit for patients with low AURKB expression, supporting its role in patients with metastatic colorectal cancer. Furthermore, the single-nucleotide polymorphism AURKB 885A4G showed a significant association in univariate analysis with an increased risk of dying. However, we did not find a statistically significant association between AURKA and any clinicodemographical parameter. Numerous studies have shown that the loss of mitotic regulation contributes to carcinogenesis. [26] [27] [28] Any inaccuracies during the process of chromosomal segregation results in either a loss or gain of chromosomes, potentially leading to upregulation of oncogenes or down regulation of tumor supressors. 29 Recent in vivo data from Ramadan et al. 20 suggests AURKB to be responsible for the prevention of chromatin decondensation during late mitosis. The authors used sperm chromatin in metaphase-arrested egg-extract to demonstrate that binding of p97 (an ATPase considered in membrane fusion and ubiquitin-dependent processes) to ubiquitinated AURKB extracts it from chromatin. This deactivation of AURKB enables chromosome decondensation, formation of the nuclear envelope and thereby nucleus reformation . In fact, the addition of active AURKB to chromatin resulted in prevention of chromatin decondensation.
AURKB is the catalytic component of a chromosomal complex, which is comprised of several additional Pharmacogenetic profiling of Aurora kinases in colorectal cancer non-catalytic subunits that direct its activity. Among others, these key substrates include survivin, inner centromeric protein, borealin and Histone H3. 4 Ota et al. 2 used transfected cells, which showed overexpression of AURKB in a tumorigenity model in BALB/c nu/nu mice. Their results indicated that cells with an AURKB overexpressing profile had a higher tumorigenity and showed a more aggressive cancerous phenotype in this mouse model than cells with a low expression profile. The same effect could be induced by using transfected cells with mutated Histone H3, leading to mitotic phosphorylation at Ser-10, which is considered to be a necessity for correct sister chromatid segregation during cell division. The authors conclude that AURKB overexpression may contribute to cancer progression by producing aneuploidy through increased mitotic phosphorylation at Histone H3 at Ser-10.
In our study, high gene expression levels of AURKB were found to be significantly associated with decreased OS. Remarkably, several independent groups discovered an association with AURKB gene expression levels and OS in astrocytoma, glioblastoma and lung cancer. 6, 14, 17 However, we could not confirm the impact of AURKA in our patient group as this has been described by different groups for colorectal cancer. 10, 30, 31 In fact, we did not find any significant association with AURKA mRNA expression or phenotypes and clinicodemographical parameters. Lam et al. 10 described protein expression of AURKA in 48.5% of colorectal cancer patients (97 out of 200), which was associated with well or moderate differentiation (P ¼ 0.004), localization of the tumor (P ¼ 0.01), expression of p16 protein (P ¼ 0.001) and inversely correlated with the expression of telomerase activity (P ¼ 0.005). Another study conducted by Carvalho et al. 31 described AURKA to affect the adenoma-to carcinoma-progression. The authors tested DNA copy number changes on chromosome 20q and found a significant upregulation of AURKA mRNA expression levels in carcinomas compared with adenomas. It should be noted that both studies focused on AURKA and did not investigate the impact of AURKB in colorectal cancer. However, one limitation of the study by Lam et al. 10 is that the authors used a heterogenous patient cohort; consisting in majority out of non-metastatic patients. As our patient cohort included only metastatic patients, we hypothesize that AURKA may impact early stages of colorectal cancer, whereas AURKB has a role in metastatic disease. In fact, Katayama et al. 32 reported AURKB expression levels to be closely related with Dukes' stage, as expression seemed to be increased in samples with a higher grade of malignancy.
There are only a very few studies which investigated the prognostic value of polymorphisms in AURKA and -B. A recent manuscript suggests AURKB 885A4G to have a role with the risk of breast cancer. Patients harboring the homozygous G-phenotype showed an increased risk for breast cancer (OR ¼ 1.45, 95% CI ¼ 1.05-2.0, P ¼ 0.02) compared with a healthy control group. 22 In our study, we found a significant association with OS implementing a nonfavorable outcome for patients homozygous for the G-allele (P ¼ 0.05, log-rank test). Furthermore, we could confirm the linkage disequilibrium described by Tchatchou et al. 22 between the AURKB polymorphisms tested. However, the functional relevance for AURKB 885A4G is still unclear; as the exchange does not seem to influence the secondary structure of AURKB mRNA nor does it create a splice site. Tchatchou et al. 22 thereby concluded that the effect of AURKB 885A4G is potentially because of the linkage of this single-nucleotide polymorphism is with another functional variant in the AURKB gene. Recently, compounds that target the non-structural components of mitosis have been developed and are presently evaluated for efficacy in phase -I and -II clinical trials. Agents like AZD-1152, (inhibits Aurora B4A), and VX-680/MK-0457 (Pan-Aurora inhibition) are showing promising results. As classical clinical staging systems often lack to describe the genetic make-up of the tumor, the concomitant assessment of biomarkers is even more important. Molecular markers in the primary specimen that are highly correlated with survival, such as AURKB, could augment standard staging information and enable us to identify patients who are most likely to benefit from a targeting agent, thereby avoiding treatment-related toxicity and morbidity. 19 However, as with all retrospective studies, this project has its limitations. One limitation is the relatively small number of patients. Second, owing to the retrospective nature of this study, the patient population was heterogeneous (as patients were pretreated with different regimen.) Nonetheless, we find a significant association of AURKB with OS, indicating a potential role of AURKB in carcinogenesis and tumor progression. These findings need to be validated in a larger retrospective study population before these results can be confirmed in a clinical setting.
